Intercontinental Wealth Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,702 shares of the biopharmaceutical company’s stock, valued at approximately $333,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares in the last quarter. Penserra Capital Management LLC raised its holdings in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences in the first quarter valued at about $143,000. Washington Trust Bank raised its holdings in shares of Gilead Sciences by 24.8% in the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 550 shares in the last quarter. Finally, Adalta Capital Management LLC bought a new stake in shares of Gilead Sciences in the first quarter valued at about $204,000. Hedge funds and other institutional investors own 74.38% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/12/intercontinental-wealth-advisors-llc-acquires-shares-of-4702-gilead-sciences-inc-gild.html.
In other Gilead Sciences news, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the sale, the executive vice president now directly owns 62,715 shares in the company, valued at approximately $5,217,260.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,269,486 over the last quarter. 1.30% of the stock is owned by company insiders.
Several equities analysts have issued reports on the company. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research note on Wednesday, September 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.92.
Shares of Gilead Sciences, Inc. (GILD) opened at $73.77 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 4.74 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a market capitalization of $96,363.46, a P/E ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the business earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.